🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Vedang Murthy Akshay Dinesan TMC Radiation Oncology Priyamvada Maitre Maneesh Singh Prachi S. Mehta Great example of curiosity --> discovery!! And now we all benefit! Strong work 👍👍

SBRT vs. Ablation for Kidney Cancer: A Game-Changer? OncoAlert 🚀🔥 #RadOnc 🧵 Ablative therapies for localized renal cell carcinoma (RCC): What’s the best approach? 📢 A new Lancet Oncology study compares SBRT, radiofrequency ablation (RFA), microwave ablation (MWA), and

We have a position for a Clinical Research Fellowship in Uro Radiation Oncology at TMC Radiation Oncology Tata Memorial Hospital and ACTREC-TMC for a 6 to 12m starting 1st April 2025. Please let me know if any students post MD or DNB are interested. It should be quite productive. 😊

🥳New OncoScan (and my first!) in IJROBP - The Red Journal from the GU editorial board "Precision Over Tradition: Transforming Prostate Cancer Treatment with SBRT" 2024 was the year of Prostate SBRT, or so it seems! 😇 FREE LINK👇🏽authors.elsevier.com/c/1kleQ1Hx52K1… Nicholas Zaorsky, MD MS Cédric Draulans

Bladder preservation is a philosophy—not just a protocol. A 15-year journey in bladder preservation at TMC Radiation Oncology . Tata Memorial Hospital ACTREC-TMC From pioneering Adaptive Radiotherapy (ART) to safely transitioning to hypofractionation, our story, in IJROBP - The Red Journal #RadOnc #bladdercancer

The incredible journey of Bladder Preservation TMC Radiation Oncology over 15 years with online adaptive radiotherapy Plan of the Day technique by Vedang Murthy! 🎊🎉 Privileged to be a part of it 🥰 Out in IJROBP - The Red Journal doi.org/10.1016/j.ijro… Anuradha Krishnan Bladder Cancer India IBCG

From @vedangmurthy @priyamvadamaitre Maneesh Singh et al: SABR clinical trials special issue; PROBE the DIL. Feasibility and safety report of PSMA-PET based focal boost in prostate SBRT. #RedJournal: tinyurl.com/redmurthy

Wonderul présentation about bladder preserving TMT treatment and patient selection at #ESTRO2025 by Priyamvada Maitre ❤️

🔥⚡️🚀Adjuvant RT after cystectomy in high-risk bladder cancer: •25–30% LRR despite chemo •Safe (<5% G3–4 toxicity, 3 RCTs) •RT ↓ LRR = worthy goal Presented by Dr. Vedang Murthy Murthy at #ESTRO2025 #BladderCancer #Radiotherapy #OncoTwitter

🔎 🇹🇷 study demonstrates that focal boost with SIB technique effectively improves PCSS in patients with localized PCa without significantly increasing toxicity #ESTRO25

🎯 SIB to IPL in PCa: large series presented by Dr Onal ⬆️10y PCSS (96.7% vs 86.7%) ⬇️LR (0.4% vs 1.5%) 🚫 added toxicity. Smart boost, better outcomes! #ESTRO25

📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

This one began with a nagging doubt. 🧵 We’ve all seen the rising enthusiasm for adding Abi to RT + ADT for high-risk prostate cancer, driven by STAMPEDE trial. But in the PSMA-PET era, is this systemic intensification always necessary? nature nature.com/articles/s4139…

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No

Felipe Couñago PhD Dr. Andrew Loblaw Can we? The initial concept of MDT-alone was deferring ADT-related toxicity in patients who want to avoid/postpone hormone treatment. It really isn't surprising that adding ADT to MDT postpones time to radiologic event, but I believe the endpoint is flawed. With MDT alone, the

Finally Managed to gather a fantastic bunch of KOLs from India 🇮🇳 Bangladesh Sri Lanka and Nepal. Discussed the nuances of PCa Mx. Plenty of friendly banter and leg pulling. Official APCCC South Asia. Paper with similarities yet differences from Advanced Prostate Cancer Consensus Conference coming soon.

Debate 3 🥊 Piet Ost Vedang Murthy 8/n

During residency, when modems crackled and PubMed barely loaded, I relied on Sem in Rad Oncol for the latest info. Contributing 2 articles to its latest issue on #prostatecancer is a full-circle moment. 🙏🏼 What Sophia Kamran, MD and Constantinos Zamboglou have put together is a masterpiece.

1️⃣ Elective Regional Nodal Irradiation in Prostate Cancer 👥 With Dr Srinivas Chilukuri, Mutlay Sayan, MD & Alan Dal Pra, MD 🎯 We cover rationale, patient selection & key trials shaping WPRT in high-risk, SBRT and post op settings. Read 📖 doi.org/10.1016/j.semr…